MediPharm Labs (MEDIF) announced the signing of a definitive supply agreement with Remidose Aerosols for the shipment of GMP-certified medicinal cannabis products to Costa Rica. Under the agreement, MediPharm Labs will supply a range of GMP-certified cannabis products including oils, tinctures, metered dose inhalers and dried flower to Remidose’s affiliated entity, Remidose LATAM. Remidose LATAM has already advanced its regulatory process, and shipment will begin once the remaining requirements are completed.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDIF:
- MediPharm Labs Poised to Gain as U.S. Moves Cannabis to Schedule III
- Medipharm Labs ‘welcomes’ executive order on cannabis reclassification
- MediPharm Labs Announces Board Changes: Michael Bumby Returns
- MediPharm Labs Enters French Medicinal Cannabis Market with First Shipment
- Medipharm Labs completes first shipment to France